Pacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.57, $0.33 worse than the analyst estimate of $0.90. Revenue for the quarter came in at $196.9 million versus the consensus estimate of $200.54 million.

GUIDANCE:

Pacira Pharma sees FY2026 revenue of $745-770 million, versus the consensus of $792.2 million.
Non-GAAP R&D expense of $105 million to $115 million;
Stock-based compensation of $54 million to $62 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.